NewCurves forwarded to FTC
This article was originally published in The Tan Sheet
Executive Summary
Claims for breast enhancement formula marketed by Rozge Cosmeceutical forwarded to FTC by the National Advertising Division of the Council for Better Business Bureaus, CBBB divisions announces July 23. Watchdog group had decided claims such as "effective in over 89% of women" and "guaranteed results" were not supported by reliable scientific evidence. Although Rozge agreed to make changes, NAD said revisions such as "over 89% of NewCurves users have been satisfied" and "satisfaction guaranteed" did not comply with "either the letter or spirit of NAD's recommendations"...
You may also be interested in...
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.